On Wednesday shares of Molycorp, Inc. (NYSE:MCP) closed at $0.38. Company’s sales growth for last 5 years was 131.80% and EPS growth for next 5 years is recorded as 15.00%. Molycorp Inc. (NYSE:MCP) has hired advisers to evaluate its capital structure, leading some analysts to fear a bankruptcy filing is imminent. CEO Geoff Bedford said on a Tuesday earnings call that the company has appointed Miller Buckfire & Co. LLC to “assist us in our efforts to strengthen our balance sheet and evaluate our capital structure going forward.” He refused to take questions about the company’s capital structure during the call.
Turtle Beach Corporation (NASDAQ:HEAR) in last trading activity decreased -6.64% to close at $1.97. Company weekly performance is -13.60% while its quarterly performance stands at -39.20%. Turtle Beach Corporation (NASDAQ:HEAR) is -86.64% away from its 52 week high. Analysts at Wedbush reiterated an “outperform” rating and set a $10.00 price target on shares of Turtle Beach Corporation (NASDAQ:HEAR) in a research note.
On last trading day Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) decreased -7.86% to close at $10.67. Its volatility for the week is 6.36% while volatility for the month is 5.53%. SUPN’s sales growth for past 5 years was 26.30% and its EPS growth for past 5 years was 67.00%. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) monthly performance is 21.25%. On March 23, 2015, the Board of Directors of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) appointed Georges Gemayel, Ph.D. to fill a vacant seat as a member of the Board of Directors of the Company. Dr. Gemayel will receive an annual Board service fee of $40,000 in 2015, which amount shall be prorated for his actual time of service in 2015.
Orexigen Therapeutics, Inc. (NASDAQ:OREX) has 9.05% insider ownership while its institutional ownership stands at 90.50%. In last trading activity company’s stock closed at $6.92. Orexigen Therapeutics, Inc. (NASDAQ:OREX) currentlygot a big breakthrough from its Light study research, which is being performed in a hurry to reject the likelihood that the company’s heftiness drug Contrave causes any heart issues and before this gets highlighted in the market.
On last trading day The Procter & Gamble Company (NYSE:PG) decreased -1.08% to close at $83.01. Its volatility for the week is 1.22% while volatility for the month is 1.26%. PG’s sales growth for past 5 years was 1.60% and its EPS growth for past 5 years was 2.80%. The Procter & Gamble Company (NYSE:PG) monthly performance is -2.91%. The Procter & Gamble Company (NYSE:PG) could stop buying a bleach activator from FutureFuel Corp. at the end of 2015, jeopardizing a contract that last year brought in 13 percent of the Clayton-based chemical maker’s revenue.